|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease显示文摘 | MEGA J L HOCHHOLZER W FRELINGER A L | 2011 | JAMA2011，306，20： | 1 |
| 2 | Prasugrel com pared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Th rombolysis in Myo cardial Infarction 44 trial显示文摘 | Wiviott S D Trenk D Frelinger A L etal | 2007 | Circulation2007，116，25： | 1 |
| 3 | Application of flow cytometry to platelet disorders显示文摘 | Linden MD Frelinger A L 3rd Barnard MR | 2004 | Semin Thromb Hemost2004，30，5： | 1 |
| 4 | Early autoimmune destruction of islet grafts is associated with a restricted repertoire of IGRP-specific CD8(+) T cells in diabetic nonobese diabetic mice显示文摘 | Wong C P Li L Frelinger J A | 2006 | Journal of Immunology2006，176，3： | 1 |
| 5 | Preconditioning ischemia attenuates molecular indices of platelet activationaggregation显示文摘 | Whittaker P Frelinger A L | 2006 | JOURNAL OF THROMBOSIS AND HAEMOSTASIS2006，4，12： | 1 |
| 6 | Targeted inhibition of the serotonin 5 HT2A receptor improves cor-onary patency in an in vivo model of recurrent thrombosis 显示文摘 | PRZYKLENK K FRELINGER A L 3RD LINDEN M D | 2010 | J Thromb Haemost2010，8，2： | 1 |
| 7 | Current options in platelet function testing 显示文摘 | Michelson A D Frelinger A L Furman M I | 2006 | Am J Cardiol2006，98，10： | 1 |
| 8 | A randomized open-label 2-period crossover design study to assess the steady-state effects of dexlansoprazole lansoprazole esomeprazole or omeprazole on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects 显示文摘 | Frelinger A L Lee R D Mulford D J | 2011 | JAm Coil Cardiol2011，57，14： | 1 |
| 9 | Platelet activation in cystic fibrosis显示文摘 | Osullivan B P Linden M D Frelinger A L | | 0，，12： | 1 |
| 10 | A randomized,2 - period,crossover design study to assess the effects of dex- lansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady - state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers 显示文摘 | Frelinger A L Lee R D Mulford D J | 2012 | Journal of the American College of Cardiology2012，59，14： | 1 |
| 11 | Soluble CD40 ligand in aspirin-treated patients undergoing cardiac catheterization 显示文摘 | GREMMEL T FRELINGER A L MICHELSON A D | 2015 | PLoS One2015，10，01： | 1 |
| 12 | Resistance to fatal central nervous system disease by mouse hepatitis virus strain JHM显示文摘 | Stohlman S A Frelinger J A Weiner L P | 1980 | J Immunol1980，124，4： | 1 |
| 13 | Application of flow eytometry to platelet disorders 显示文摘 | Linden M D Frelinger A L 3 rd Barnard M R | 2004 | Semin Thromb Hemost2004，30，5： | 1 |
| 14 | Platelet activation in cystic fibrosis 显示文摘 | Osullivav B P Linden M D Frelinger A L | 2005 | Bllod2005，105，12： | 1 |
| 15 | Clinical out- comes using a platelet function - guided approach for secondary prevention in patient with ischemic stroke or transient ischemic attack 显示文摘 | Depta J K Frelinger A L Htun P | 2012 | Stoke2012，106，24： | 1 |
| 16 | Indices of platelet activation and the stability of coronary artery disease 显示文摘 | LINDEN M D FURMAN M I FRELINGER A L 3rd | 2007 | J Thromb Haemost2007，5，4： | 1 |
| 17 | Clopi- dogrel Pharmacokinetics and Pharmacodynamics Vary Widely De- spite Exclusion or Control of Polymorphisms ( CYP2C19, ABCB1, PONI ), Noncompliance, Diet, Smoking, Co- Medications (Inclu- ding Proton Pump Inhibitors ), and Pre -Existent Variability in Platelet Function显示文摘 | FRELINGER A L 3RD BHATT D L LEE R D | 2013 | J Am Coil Cardiol2013，61，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员